Showing results (161-170 of 192) with videos related to
Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agentsJanet E Dancey, Kevin K Dobbin, Susan Groshen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcomeJan Brabender, Henning Usadel, Ralf Metzger, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2011
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trialBarbara J Gitlitz, Denice D Tsao-Wei, Susan Groshen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trialSteven G DuBois, Louis Chesler, Susan Groshen, et al.Pediatric Blood & Cancer|September 11, 2010
Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastomaAlekist Quach, Lingyun Ji, Vikash Mishra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium studyLars M Wagner, Judith G Villablanca, Clinton F Stewart, et al.Urology|December 17, 2013
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshopJonathan P Jarow, Seth P Lerner, Paul G Kluetz, et al.International Journal of Radiation Oncology, Biology, Physics|December 16, 2022
Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory NeuroblastomaKevin Campbell, Susan Groshen, Angela C Evans, et al.Pediatric Blood & Cancer|July 2, 2013
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortiumBarry J Maurer, Min H Kang, Judith G Villablanca, et al.Oncotarget|September 9, 2017
Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126Anat Erdreich-Epstein, Alok R Singh, Shweta Joshi, et al.Pageof 20